Methods of diagnosing breast cancer

• US 6,762,020 B1
• Filed: 08/18/2000
• Issued: 07/13/2004
• Est. Priority Date: 03/15/1999
• Status: Expired due to Term

• Current Assignee: Abbvie Biotherapeutics Inc. (Abbvie Incorporated)
• Original Assignee: Protein Design Labs, Inc. (PDL BioPharma, Inc.)
• Inventors: Gish, Kurt C., Mack, David H.
• Primary Examiner(s): Myers, Carla J.
• Assistant Examiner(s): Johannsen, Diana B.
• Application Number:
  US09/642,034
• Time in Patent Office: 1,425 Days
• Field of Search: 435/6, 435/287.2, 530/350, 536/23.5, 536/24.31
• US Class Current: 435/6.16
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/57415 of breast

Abstract

Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.

Claims

1. A method of diagnosing breast cancer in a human individual comprising:

a) determining the expression of a gene encoding an amino acid sequence of SEQ ID NO;

5 in a first breast tissue sample obtained from a human individual; and

b) comparing the expression of said gene in the first breast tissue sample to expression of said gene in a normal breast tissue sample;

whereby the overexpression of said gene in the first breast tissue sample indicates breast cancer in said human individual.

2. The method of claim 1, wherein said normal breast tissue sample is obtained from said human individual.

3. The method of claim 1, wherein said normal breast tissue sample is obtained from a second individual.

4. The method of claim 1, wherein said gene comprises a nucleic acid sequence of SEQ ID NO:

4.

5. The method of claim 1, wherein said expression is measured using a labeled nucleic acid probe.

6. The method of claim 1, wherein said expression is measured utilizing a biochip comprising the sequence of SEQ ID NO:

4.